DE60307106T2 - 9,11-cycloendoperoxyd prodrugs von prostaglandinanalogen für die behandlung von okularer hypertension und glaukoma - Google Patents

9,11-cycloendoperoxyd prodrugs von prostaglandinanalogen für die behandlung von okularer hypertension und glaukoma Download PDF

Info

Publication number
DE60307106T2
DE60307106T2 DE60307106T DE60307106T DE60307106T2 DE 60307106 T2 DE60307106 T2 DE 60307106T2 DE 60307106 T DE60307106 T DE 60307106T DE 60307106 T DE60307106 T DE 60307106T DE 60307106 T2 DE60307106 T2 DE 60307106T2
Authority
DE
Germany
Prior art keywords
compound
compound according
alkyl
carbon atoms
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60307106T
Other languages
German (de)
English (en)
Other versions
DE60307106D1 (de
Inventor
John Kah-Hiing Newport Coast LING
Wu Irvine YANG
Jinsong Foothill Ranch NI
Haiqing Irvine YUAN
D. Diane Newport Beach TANG-LIU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Application granted granted Critical
Publication of DE60307106D1 publication Critical patent/DE60307106D1/de
Publication of DE60307106T2 publication Critical patent/DE60307106T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/02—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 2
    • C07D317/06—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 2 condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE60307106T 2002-08-05 2003-08-04 9,11-cycloendoperoxyd prodrugs von prostaglandinanalogen für die behandlung von okularer hypertension und glaukoma Expired - Fee Related DE60307106T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US212437 1988-06-28
US10/212,437 US6864282B2 (en) 2002-08-05 2002-08-05 9,11-cycloendoperoxide pro-drugs of prostaglandin analogues for treatment of ocular hypertension and glaucoma
PCT/US2003/024305 WO2004013119A1 (en) 2002-08-05 2003-08-04 The 9, 11-cycloendoperoxide pro-drugs of prostaglandin analogues for treatment of ocular hypertension and glaucoma

Publications (2)

Publication Number Publication Date
DE60307106D1 DE60307106D1 (de) 2006-09-07
DE60307106T2 true DE60307106T2 (de) 2007-02-22

Family

ID=31187772

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60307106T Expired - Fee Related DE60307106T2 (de) 2002-08-05 2003-08-04 9,11-cycloendoperoxyd prodrugs von prostaglandinanalogen für die behandlung von okularer hypertension und glaukoma

Country Status (9)

Country Link
US (1) US6864282B2 (enExample)
EP (2) EP1527063B1 (enExample)
JP (1) JP2005539014A (enExample)
AT (1) ATE334123T1 (enExample)
AU (1) AU2003261352A1 (enExample)
CA (1) CA2494146A1 (enExample)
DE (1) DE60307106T2 (enExample)
ES (1) ES2268433T3 (enExample)
WO (1) WO2004013119A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7070768B2 (en) * 2003-09-25 2006-07-04 Allergan, Inc. Method for imparting artificial tan to human skin
GB0501192D0 (en) * 2005-01-20 2005-03-02 Resolution Chemicals Ltd Stable prostaglandin-containing compositions
WO2010102078A1 (en) 2009-03-04 2010-09-10 Allergan, Inc. Enhanced bimatoprost ophthalmic solution
US7851504B2 (en) * 2005-03-16 2010-12-14 Allergan, Inc. Enhanced bimatoprost ophthalmic solution
EP1916002B1 (en) 2005-08-02 2014-03-05 Santen Pharmaceutical Co., Ltd. Method for prevention of degradation of thermally unstable substance
WO2007111806A2 (en) 2006-03-23 2007-10-04 Massachusetts Eye And Ear Infirmary Cyclopentane heptanoic acid compounds for reducing body fat
US20110293549A1 (en) 2009-02-03 2011-12-01 Athena Cosmetics, Inc. Composition, method and kit for enhancing hair
US9522153B2 (en) 2009-12-22 2016-12-20 Allergan, Inc. Compositions and methods for lowering intraocular pressure
ES2687494T3 (es) 2011-01-19 2018-10-25 Topokine Therapeutics, Inc. Métodos y composiciones para reducir la grasa corporal
US8426471B1 (en) 2011-12-19 2013-04-23 Topokine Therapeutics, Inc. Methods and compositions for reducing body fat and adipocytes
CA2869676C (en) 2012-11-21 2015-06-23 Topokine Therapeutics, Inc. Uses and compositions comprising a thiazolidinedione and oleic acid for locally increasing subcutaneous fat
NO2753788T3 (enExample) 2013-05-10 2018-06-16
WO2014186504A1 (en) 2013-05-15 2014-11-20 Topokine Therapeutics, Inc. Methods and compositions for topical delivery of prostaglandins to subcutaneous fat
US9115109B2 (en) * 2013-08-15 2015-08-25 Chirogate International Inc. Processes and intermediates for the preparations of isomer free prostaglandins
US10188661B2 (en) 2014-06-27 2019-01-29 Topokine Therapeutics, Inc. Topical dosage regimen
EP3675866B1 (en) 2017-09-01 2023-08-02 East Carolina University Ex vivo methods for activating immune cells

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4599353A (en) * 1982-05-03 1986-07-08 The Trustees Of Columbia University In The City Of New York Use of eicosanoids and their derivatives for treatment of ocular hypertension and glaucoma
US4867915A (en) * 1986-05-21 1989-09-19 Syntex (U.S.A.) Inc. 16-Substituted polyunsaturated hexadecanoic fatty acids
ES2213504T1 (es) 1988-09-06 2004-09-01 Pfizer Health Ab Derivados de prostaglandina para el tratamiento del glaucoma o hipertension ocular.
US5767154A (en) 1991-02-07 1998-06-16 Allergan 5-trans-prostaglandins of the F series and their use as ocular hypotensives
US5352708A (en) * 1992-09-21 1994-10-04 Allergan, Inc. Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US5385945A (en) 1992-10-21 1995-01-31 Allergan, Inc. 7-(5-substituted cyclopentyl) and (5-substituted cyclopentenyl) heptyl alcohols, heptylamines and heptanoic acid amides, and method of lowering intraocular pressure in the eye of a mammal by administration of these novel compounds
US5510383A (en) * 1993-08-03 1996-04-23 Alcon Laboratories, Inc. Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension
ATE326972T1 (de) 1997-10-13 2006-06-15 R Tech Ueno Ltd Heilende zusammensetzung für intraokulare hypertension oder glaukom
US6066671A (en) 1997-12-19 2000-05-23 Alcon Laboratories, Inc. Treatment of GLC1A glaucoma with 3-benzoyl-phenylacetic acids, esters, or amides
DE60137335D1 (de) 2000-08-07 2009-02-26 Univ Vanderbilt Nachweis der COX-2 Aktivität und von Anandamid-Metaboliten

Also Published As

Publication number Publication date
US20040023954A1 (en) 2004-02-05
EP1527063B1 (en) 2006-07-26
ES2268433T3 (es) 2007-03-16
JP2005539014A (ja) 2005-12-22
DE60307106D1 (de) 2006-09-07
ATE334123T1 (de) 2006-08-15
US6864282B2 (en) 2005-03-08
EP1731516A3 (en) 2007-01-03
AU2003261352A1 (en) 2004-02-23
EP1527063A1 (en) 2005-05-04
EP1731516A2 (en) 2006-12-13
CA2494146A1 (en) 2004-02-12
WO2004013119B1 (en) 2004-05-06
WO2004013119A1 (en) 2004-02-12

Similar Documents

Publication Publication Date Title
DE60307106T2 (de) 9,11-cycloendoperoxyd prodrugs von prostaglandinanalogen für die behandlung von okularer hypertension und glaukoma
DE69511181T2 (de) Mittel für Behandlung der Leber-Gallenerkrankungen
US5607978A (en) Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
DE69716226T2 (de) Difluoroprostaglandin-Derivate und ihre Anwendung
DE3850676T2 (de) Hypotensive okulare Mittel.
DE69714023T2 (de) Cyclopentane heptan(ene)säure, 2-heteroarylalkenylderivate als therapeutisches mittel
DE69824966T2 (de) Aromatische c16-c20-substituierte tetrahydro-prostaglandine verwendbar wie fp agoniste
US6107338A (en) Aromatic C16 -C20 -substituted tetrahydro prostaglandins useful as FP agonists
DE69613693T2 (de) 2-heteroarylalkenylderivate der cyclopentano-heptan(heptaen)säure als therapeutisches mittel zur behandlung des erhöhten augeninnendruckes
DE60219614T2 (de) 3, 7 thiaprostansäurederivate als mittel zur verminderung des augeninnendruckes
DE69705421T2 (de) 15-fluoro-prostaglandine als augendrucksenkende mittel
DE69130586T2 (de) Behandlung von Pankreaskrankheit mit 15-keto-Prostaglandin E-Derivaten
DE69118978T2 (de) Behandlung von entzündlichen Erkrankungen mit 15-Ketoprostaglandinen
US5866602A (en) Keto-substituted tetrahydrofuran analogs of prostaglandins as ocular hypotensives
DE69918433T2 (de) C11-oxymyl- and hydroxylamino-prostaglandine und ihre anwendung als arzneimittel
AT395421B (de) Verfahren zur herstellung von neuen cyclopenthylethern
DE69024744T2 (de) Behandlung der hepatobilären Erkrankung mit 15-Ketoprostaglandin-Derivaten
DE69032000T2 (de) Behandlung kardialer Dysfunktion mit 15-Ketoprostaglandinderivaten
DE69023459T2 (de) Behandlung von pulmonarer Disfunktion mit 15-Keto-prostaglandin-Derivaten.
US6531614B2 (en) Method of prostaglandin synthesis
CA2041240C (en) Biochemical treatment with 15-dehydroxy-16-oxoprostaglandin compounds
EP0045842B1 (de) Heterocyclische Verbindungen, diese enthaltende Arzneimittel und Verfahren zur Herstellung dieser heterocyclischen Verbindungen und Arzneimittel
US5656635A (en) 5-trans-alcohols and their use as ocular hypotensives
US5767154A (en) 5-trans-prostaglandins of the F series and their use as ocular hypotensives
EP0741687B1 (de) Neue leukotrien-b4-derivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee